CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced that its Chief Executive Officer, Scott Minick, and its Founder and an Associate Professor at Harvard Medical School, Omid Farokhzad, M.D., have been awarded the prestigious Ernst & Young New England Entrepreneur of the Year in the category of Life Sciences. The Ernst & Young award recognizes accomplished entrepreneurs for their development of new technologies, improvement of quality of life, and creation of strong and vibrant corporations. Mr. Minick and Dr. Farokhzad were honored last night at an event hosted by Ernst & Young in Boston, Massachusetts.
